Pompe Disease Market Set for Expansion During the Forecast Period (2026-2036) as Growth is Fueled by Next-Generation ERTs, Newborn Screening, and Pipeline Innovation | DelveInsight
The Pompe disease market is estimated to change significantly during the forecast period (2026–2036), owing to the launch of novel therapies including MZE001 (S-606001; Shionogi and Maze Therapeutics), AT845 (Astellas Pharma), AB-1009 [AskBio (Bayer)], DNL952 (Denali Therapeutics),...
Covered in this story
Call it yourself
No calls on $MAZE yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Maze Therapeutics Inc →Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.